- FR
- NL
No.
The speed with which the vaccines have been developed is due to (1) the removal of administrative barriers, (2) the priority given to research and development of new COVID-19 vaccines, (3) rapid production and (4) the financial resources that were immediately made available. At no time there was any concession made to the quality and safety of the COVID-19 vaccines. By giving the highest priority to the COVID-19 studies, many years were gained. The COVID-19 vaccines meet the same strict requirements as all previously developed vaccines (e.g. seasonal influenza, etc). Only after sufficient demonstration that a COVID-19 vaccine is of good quality, effective and safe, the European Medicines Agency (EMA) approves it for use by the general public.